Neuropeptide Y (NPY) has been implicated in depression, emotional processing and stress response. Part of this evidence originates from human single-nucleotide polymorphism (SNP) studies. In the present study, we report that a SNP in the rat Npy promoter (C/T; rs105431668) affects in vitro transcription and DNA-protein interactions. Genotyping studies showed that the C-allele of rs105431668 is present in a genetic rat model of depression (Flinders sensitive line; FSL), while the SNP's T-allele is present in its controls (Flinders resistant line; FRL). In vivo experiments revealed binding of a transcription factor (CREB2) and a histone acetyltransferase (Ep300) only at the SNP locus of the FRL. Accordingly, the FRL had increased hippocampal levels of Npy mRNA and H3K18 acetylation; a gene-activating histone modification maintained by Ep300. Next, based on previous studies showing antidepressant-like effects of physical activity in the FSL, we hypothesized that physical activity may affect Npy's epigenetic status. In line with this assumption, physical activity was associated with increased levels of Npy mRNA and H3K18 acetylation. Physical activity was also associated with reduced mRNA levels of a histone deacetylase (Hdac5). Conclusively, the rat rs105431668 appears to be a functional Npy SNP that may underlie depression-like characteristics. In addition, the achieved epigenetic reprogramming of Npy provides molecular support for the putative effectiveness of physical activity as a non-pharmacological antidepressant.
Introduction
One of the few candidate genes showing reproducibility among genetic association studies of depression is neuropeptide Y (NPY). [1] [2] [3] [4] [5] NPY is widely expressed in the central nervous system and has been suggested to act as an anxiolytic peptide that confers mental resilience [6] [7] [8] [9] through activation of limbic NPY-Y1 receptors. 10 In addition, NPY was found to regulate neurogenesis in the hippocampus; 11 a brain region appearing dysfunctional and with reduced volumes in severely depressed patients. [12] [13] [14] [15] [16] The human NPY harbors functional single-nucleotide polymorphisms (SNPs) that control NPY's transcriptional activity. 17 One of these SNPs (rs16147: C/T) is known to affect emotional processing 3, 17, 18 and its effect is modulated by early-life adversities. 5, [19] [20] [21] However, the downstream molecular consequences of functional NPY SNPs, like rs16147, remain unknown and in vivo experimental research has been lacking due to the absence of suitable genetic models.
The amino-acid sequence of the mature human NPY is identical to the rat and mouse sequences, and all three species have conserved NPY promoter sequence elements, including the TATA-and GC-boxes. 22 This makes rodents a suitable model for translational gene-regulatory research of Npy. A Sprague-Dawley rat model that displays a genetic susceptibility to depressive behavior is the Flinders sensitive line (FSL) which, compared with its controls (Flinders resistant line; FRL), shows changes consistent with the NPYergic hypothesis of depression. [23] [24] [25] [26] [27] Apart from depression-like behavioral characteristics like psychomotor retardation and sleep disturbances, 28 the FSL have reduced hippocampal volumes, 29 show a dysfunctional regulation of glutamate transmission 30 and exhibit emotional memory impairments. 31 Additionally, physical activity in the form of wheel running has been shown to increase cell proliferation in the hippocampus of the FSL and to have antidepressant-like effects. 32, 33 However, the genetic components underlying the observed depression-like phenotypes and molecular characteristics of this genetic model have never been explored. In this report, we hypothesized that hippocampal dysregulation of Npy in the FSL may be caused by functional SNPs in the promoter region, similar to rs16147 in humans. Accordingly, we found a functional SNP (C/T; rs105431668) located in Npy's core promoter, between the gene's TATA-box and the transcription start site (TSS). In vitro and in vivo experiments demonstrated that this SNP affected gene expression levels and was responsible for DNA-protein interactions which, in turn, were associated with distinct epigenetic states of Npy. Additionally, the latter epigenetic states were found to be affected by physical activity, providing molecular evidence for the putative effectiveness of physical activity as a nonpharmacological antidepressant.
Materials and methods
Tissue samples. Tissue samples included hippocampi from adult FRL and FSL rats that were dissected and immediately stored at À 70 1C until subsequent experimental analyses. The number of samples used for each experiment is given in the corresponding methodological section. All experiments were approved by the Ethical Committee for protection of animals at the Karolinska Institutet.
DNA/RNA extraction and reverse transcription. DNA was isolated using the QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany) or a standard isopropanol-based extraction protocol. Total RNA was isolated using the RNeasy Lipid Tissue Mini Kit (Qiagen) and was treated with DNase I (Qiagen) to eliminate contaminating DNA. The RNA quality was examined on a 1% agarose gel and total DNA/RNA concentrations were determined spectrophotometrically using the NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies Inc., Wilmington, DE, USA). Complementary DNA was synthesized by reverse transcription of total RNA using SuperScript III First-Strand Synthesis System for real-time PCR (RT-PCR) (Invitrogen, Carlsbad, CA, USA). DNA/complementary DNA was stored at À 20 1 C and RNA at À 70 1C.
DNA sequencing. DNA sequencing was performed to examine genetic differences between FRL and FSL. For this reason, the proximal upstream promoter and all coding exons of Npy were sequenced in FRL (n ¼ 6) and FSL (n ¼ 6). Genomic DNA was used for sequencing of the proximal promoter, which was restricted to 768 nucleotides (nts) upstream from the TSS ( À 768 to þ 1), and complementary DNA was used for sequencing of the amino-acid-coding regions. Sequencing reactions were performed bidirectionally on an ABI 3730 DNA Analyzer (Applied Biosystems Inc., Foster City, CA, USA), using the BigDye Terminator v.3.1 Cycle Sequencing kit (Applied Biosystems). The sequencing primers used are given in Supplementary Materials/Methods. Genetic variation was assessed using the Geneious software version 4.8 (Biomatters Ltd, Auckland, New Zealand 34 ).
SNP genotyping by pyrosequencing. The three promoter SNPs identified in the initial genetic screening by DNA sequencing (rs8153612 (A/G), rs107377172 (A/C), rs105431668 (C/T)) were subsequently genotyped in a larger separate set of FRL (n ¼ 19) and FSL (n ¼ 24) using pyrosequencing methodology. Pyrosequencing was performed on a PSQ 96 MA platform according to the manufacturer's protocol (Qiagen). The primer pairs used for genotyping are given in Supplementary Materials/Methods.
Gene expression by quantitative RT-PCR. Quantitative RT-PCR (qRT-PCR) was performed to measure mRNA levels of candidate genes using whole hippocampal tissue. First, Npy mRNA levels were measured in naive FRL and FSL rats (n ¼ 8 FRL and n ¼ 10 FSL). We have previously shown that the rat Npy mRNA exists in two splice variants; a 'long' protein-coding variant and a 'short' putatively noncoding variant. 35 All Npy mRNA experiments performed in this study were designed to detect only the coding variant. Following wheel running experiments (see section below), both Npy mRNA levels (n ¼ 8 FSL, n ¼ 7 FSL-runners; outliers: n ¼ 2 FSL and n ¼ 1 FSL-runner) and mRNA levels of candidate histone modifying enzymes (histone acetyltransferase Ep300, and nuclear located class I, II, III and IV histone deacetylases (HDACs); n ¼ 6 FSL, n ¼ 6 FSL-runners; outliers: n ¼ 1 FSL and n ¼ 1 FSL-runner) were measured. TaqMan Gene Expression Assays (Applied Biosystems) or Power SYBR Green (Applied Biosystems) was used for qRT-PCR experiments. Amplifications of target genes and housekeeping gene were performed in triplicates using complementary DNA. Gene amplifications were performed on an ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems) and data were obtained as threshold cycle (Ct Gene expression of Npy by in situ hybridization. To measure Npy mRNA levels in distinct hippocampal regions (cornu ammonis 1 (CA1), cornu ammonis 3 (CA3) and dentate gyrus), in situ hybridization experiments were carried out in FRL (n ¼ 9) and FSL (n ¼ 6). The hybridization protocol used was as previously described. 36 Luciferase reporter assay. A luciferase reporter assay was used to investigate the putative functionality of the three SNPs located in the Npy promoter region of FRL/FSL. The upstream Npy promoter region (containing all the three SNPs: 5 0 -rs8153612-rs107377172-rs105431668-3 0 ) and the core promoter region (containing only rs105431668; located between the gene's TATA-box and the TSS), were individually cloned into the KpnI and BglII sites of a pGL3 Basic Luciferase Reporter Vector (Promega Corp., Fitchburg, WI, USA). The empty pGL3 Basic Luciferase Reporter vector without any insert and a control-Luciferase vector with the SV40 enhancer and promoter were used as negative and positive controls, respectively. A Renilla luciferase vector driven by a Pol III promoter was used to control for transfection efficiency. Construct transfections were performed in quadruplicates and luciferase readings were taken as singlets. Ratios of firefly to Renilla luciferase readings were taken for each experiment and normalized to the activity of the control construct to produce fold differences in luminescence. For further detailed information see Supplementary Materials/Methods.
In silico and in vitro analyses of DNA-protein interactions. An in silico analysis of the putative transcription factors (TFs) binding to the rs105431668 region was performed using ConSite, 37 which revealed a putative cyclic adenosyl monophospate responsive element-binding protein (CREB)-binding site. Electrophoretic mobility shift assay (EMSA) was then used to investigate in vitro DNA-protein interactions at the rs105431668 locus. EMSA was performed using the LightShift Chemiluminescent EMSA kit according to the manufacturer's protocol (Thermo Fisher Scientific Inc., Rockford, IL, USA). Competition reactions were performed with 200-fold molar excess of unlabeled ('cold') DNA probes. Antibody (supershift) reactions were performed with the addition of 2 ml anti-CREB1 (ab5803; Abcam plc, Cambridge, England). The probes used were: FRL probe (the T-allele of rs105431668 is underlined); 5 0 -ATAAAAGCCCGTTGGTG ACCCGCTCTACGCAT-3 0 , FSL probe (the C-allele of rs105431668 is underlined); 5 0 -ATAAAAGCCCGTTGGCG ACCCGCTCTACGCAT-3 0 . Note that the FRL/FSL probes are identical except for the SNP locus.
In vivo chromatin immunoprecipitation. To investigate in vivo DNA-protein interactions and histone modifications (HMs), chromatin immunoprecipitation (ChIP) experiments were performed according to Martens et al. 38 for a number of candidate TFs and coactivators (TF ChIP), and for HMs (HM ChIP). The antibodies used for TF ChIPs were the following: anti-CREB1 (1:50 dilution; #9197, Cell Signaling Technology Inc., Danvers, MA, USA), anti-CREB2 (also designated activating TF 4 (ATF4), 1:200; sc-200, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-ATF2 (1:200; sc-187, SantaCruz), anti-E1A-binding protein p300 (Ep300, 1:200; sc-584, SantaCruz), anti-acetyl-Ep300/CREB-binding protein (acetylp300/CREBBP aka CBP, 1:25; #4771, Cell Signaling), anti-p300/CBP-associated factor (PCAF, 1:25; #3378, Cell Signaling), and anti-immunoglobulin G (IgG, 2 ml; #2729, Cell Signaling) as negative control. The reactions for HM ChIPs included: anti-histone 3 lysine 18 acetylation (H3K18ac, 3 mg; ab1191, Abcam), anti-histone 3 (H3, 2 mg; ab1791, Abcam), and anti-histone 3 lysine 27 tri-methylation (H3K27me3, 4 mg; ab6002, Abcam) and no antibody [Ab( À )] as negative controls. The TF ChIPs were performed both for a 'target' region (that is, containing the rs105431668 locus) and a 'negative' region (that is, upstream from and not containing the rs105431668 locus) in FRL and FSL (n ¼ 6/ group; outliers: n ¼ 2 FRL for CREB2, ATF2 and Ep300). The HM ChIPs were performed for a region close to Npy's TSS in FRL and FSL (n ¼ 6/group for H3K18ac, H3K27me3 and Ab( À ); n ¼ 3/group for H3). HM ChIPs were also performed following wheel running experiments (described in the next section) in FSL and FSL-runners (H3K18ac and Ab(-): n ¼ 6 FSL and n ¼ 5 FSL-runners, H3: n ¼ 4 FSL and n ¼ 4 FSLrunners; outlier: n ¼ 1 FSL). For further detailed information see Supplementary Materials/Methods.
Wheel running experiments. To investigate putative epigenetic effects of physical activity on Npy, wheel running experiments were performed as previously described. 32 In brief, FSL animals were individually housed with either free access or no access to running wheels during a period of 5 weeks. Running data were sampled 48 times per day using a computer-based data system with customized software. Following wheel running experiments, hippocampi were dissected and mRNA levels of candidate genes were measured using qRT-PCR as described previously.
Statistical analyses. Data are presented as mean values and error-bars represent ± 1 s.e.m. Mann-Whitney U-tests were used for group comparisons. Statistical significance was set at Po0.05. All analyses were performed using IBM SPSS Statistics (IBM Corporation, Armonk, NY, USA). Samples with values showing striking (arbitrary) difference from the rest of the group were considered outliers and were excluded from the statistical analyses.
Results
Genotypic and gene expression differences of Npy between FSL and FRL. DNA sequencing of the upstream promoter and the coding regions of Npy showed that the FSL differed genetically from the FRL only in the promoter region. More specifically, we found three genetic variations in the proximal promoter of Npy. When cross-referencing with NCBI's SNP database (Entrez dbSNP), all three nt substitutions were found to be registered as rat (Rattus norvegicus) SNPs. The reference SNP (rs) numbers, as reported in genomic build 136, were the following: (1) rs8153612 (A/G), (2) rs107377172 (A/C), (3) rs105431668 (C/T); numbered 5 0 to 3 0 (Figure 1) . Subsequent SNP genotyping studies revealed the presence of two distinct haplotypes in the two strains. More specifically, all of the FRL were homozygous for the G-A-T haplotype, whereas 70% of the FSL were homozygous for the A-C-C haplotype and 30% of the FSL were heterozygous for the two haplotypes. Gene expression analyses using qRT-PCR and whole hippocampal homogenates showed that the Npy mRNA levels were decreased in FSL compared with FRL (Po0.05; Figure 2a) . In situ hybridization experiments using a separate group of animals confirmed the Npy decrease in FSL and showed that it was more pronounced in the CA1 hippocampal region (Po0.01; Figure 2b ). A similar trend was also present in the dentate gyrus (P ¼ 0.05) and in the CA3 (P ¼ 0.11) regions of the hippocampus (Figure 2b ).
In vitro functionality of the rs105431668 (C/T) SNP. Two of the identified SNPs were located close to conserved Npy promoter elements. Specifically, the second SNP (rs107377172; A/C) was located À 3 nt from Npy's GC-box and the third SNP (rs105431668; C/T) was located þ 10 nt from the TATA-box and À 15 nt from the TSS (Figure 1) . In order to examine putative SNP functionality, we used a luciferase reporter assay and luminescence data were verified in two different cell lines (HCT-116 and U2OS). Figure 3a indicates the names of the cloned fragments and the different SNP haplotypes contained in these clones. Data were first generated using constructs containing either upstream promoter clones (that is, clones with the complete FRL or FSL haplotype) or core promoter clones (that is, clones containing only rs105431668; the SNP closest to the TATA-box). The clones containing the FRL genotype had a positive effect on gene expression, both in the upstream form (Po0.05; Figure 3b ) and in the core (T-allele) promoter form (Po0.05; Figure 3c) . Results from the core clones suggested that rs105431668 was the functional SNP. However, we could not exclude the possible involvement of the two remaining SNPs (rs8153612 and rs107377172) in gene expression regulation. An FRL clone with a chimeric haplotype (that is, A-C-T; Figure 3a ) was able to resolve this issue. This clone contained the first two upstream FSL SNPs and the third (putatively functional) core FRL SNP. By comparing the FSL-upstream/FRL-core clone's activity with the upstream FSL clone, we were able to confirm that the T-allele of rs105431668 (present in all FRL rats) determined the in vitro haplotype-driven transcriptional upregulation (Po0.05; Figure 3d ). EMSA was then performed to study putative in vitro DNA-protein interactions at the rs105431668-containing region. Significantly, we observed a strong mobility shift band only when using an FRL probe (containing the T-allele of rs105431668; Figure 3e , lanes 2 and 4) but not when using an FSL probe (containing the C-allele of rs105431668; Figure 3e, lanes 6 and 8) . The in silico analysis, which was performed to predict putative TFs binding to the rs105431668-containing region, indicated a non-consensus cyclic adenosyl monophospate response element-binding site only under the presence of the T-allele. There are several cyclic adenosyl monophospate response element-binding proteins within the ATF/CREB family, including CREB1, CREB2 (also designated ATF4) and ATF2. Before proceeding with in vivo analyses of these TFs, we also performed EMSA with an anti-CREB1 antibody. However, the latter experiment argued against an in vitro binding of CREB1, as no supershift was observed (Figure 3e ; lane 4). In summary, these data suggest a functional DNAprotein interaction within Npy's promoter region under the presence of rs105431668's T-allele.
In vivo allele-specific epigenetic states of Npy. To study putative in vivo protein-DNA interactions, we performed ChIP experiments for three members of the ATF/CREB family (CREB1, CREB2 and ATF2) using hippocampal tissue from FSL/FRL animals. As members of the ATF/ CREB family are known to recruit transcriptional coactivators with histone modifying properties, we also examined interactions with Ep300 and PCAF using the same technique. ChIP was performed both for a target region (the region containing rs105431668) and an upstream negative region (not containing rs105431668). The ChIP data revealed an enrichment of CREB2 and Ep300 in the target region of the FRL, but not that of the FSL (Po0.05; Figure 4a ). There was also an enrichment of Ep300 when using a second antibody against its more active (acetylated) form (Po0.05; Figure 4a ). None of these enrichments were present in the negative region, suggesting specificity to the rs105431668 locus (Supplementary Figure S1a) . In line with these data, and as Ep300 is known to acetylate lysine 18 of histone 3 -116 and U2OS) , the different luciferase constructs demonstrated that the rs105431668's T-allele (present in homozygosity only in the FRL rats) leads to increased transcription in vitro compared with the C-allele (present only in the FSL rats). (e) Lanes one and five of the mobility shift assays mark the positions of the free (non-interacting) FRL and FSL probes, respectively. Lane two demonstrates an in vitro DNA-protein interaction after the addition of nuclear extract, which is shown as a gel-shift next to the arrow. A strong shift was only generated by the FRL probe (containing the T-allele of rs105431668; lane 2) and not by the FSL (C-allele) probe (lane 6). Lane three shows the reduction of the DNA-protein interaction that occurs after the addition of 'cold' (unlabeled) probe and indicates specificity in the type of DNA-protein interaction between FRL probe and components of the nuclear extract. Lanes 4 and 8 test for putative supershifts by the addition of an antibody (Ab) against CREB1. No supershifts were observed indicating that CREB1 isn't responsible for the in vitro DNA-protein interaction. Convincingly, however, the initial gel shift is reestablished at the same position for FRL (lane 4) and, again, no shift is observed for FSL (lane 8). *Po0.05.
(H3K18ac), subsequent ChIP experiments showed increased levels of H3K18ac at the Npy region of FRL compared with FSL (Po0.01; Figure 4b ). No such difference was found for an Ep300-unrelated HM (H3K27me3) or for levels of H3 (Supplementary Figure S1b) . Collectively, these results suggest that dysregulation of Npy in the hippocampus of FSL is a result of epigenetic modifications that are associated with the rs105431668 genotype. Specifically, the FRL's SNP genotype is associated with recruitment of both CREB2 and the acetylated form of Ep300. Ep300, in turn, leads to a transcriptionally active chromatin state; indicated by the increased levels of both H3K18ac and Npy mRNA in the FRL.
Physical activity is associated with an epigenetic reprogramming of Npy. Physical activity in the form of wheel running was associated with an increase in hippocampal Npy mRNA levels in FSL-runners, compared with FSL rats with no access to running wheels (Po0.05; Figure 5a ). In accord with the histone-modification findings using naive FSL/FRL rats, the upregulation of Npy's mRNA in FSL-runners was associated with increased levels of H3K18ac (Po0.05; Figure 5b ). Again, there was no difference in levels of H3 (Supplementary Figure S2a) . As an exploratory analysis of the underlying mechanism leading to increased acetylation levels of H3K18, we measured the mRNA levels of Ep300 and all known nuclear HDACs. Notably, we found that there was a downregulation of Hdac5 mRNA levels in the running group (Po0.01; Figure 5c ). No differences were found in the mRNA levels of Ep300 (Supplementary Figure S2b) or all other tested HDACs (Supplementary Figure S2c) . These data suggest that physical activity can lead to an activating epigenetic reprogramming of Npy through the downregulation of Hdac5, which potentially drives the increase of H3K18ac and is not dependent on the genetic variation present at the rs105431668 SNP locus.
Discussion
General. NPY is suggested to confer resilience to both depression and anxiety; two disorders that are influenced by common genetic factors. [39] [40] [41] This is supported by evidence showing that NPY is reduced in the cerebrospinal fluid of depressed subjects 2, 42 and in post-mortem brains of suicide victims. 43 In addition, polymorphisms in the human NPY gene have been associated with depression 1,2,4,5 and a genetic variation in the NPY promoter (SNP rs16147) has been shown to control NPY's transcriptional activity and to affect emotional processing and stress response. 3, 17, 18 Studies in the FSL genetic model of depression, have also consistently been in line with NPY's role in the pathophysiology of the disorder. 23, 24, 27, 35, 36, [44] [45] [46] [47] [48] The present investigation was the first to hypothesize and demonstrate that the observed dysregulation of Npy in the FSL is a result of a functional SNP variation (rs105431668) resembling human rs16147. It should, however, be noted that, on the level of the individual SNPs, a cross-species comparison is not possible as the human rs16147 and the rat rs105431668 are not orthologous (the rat SNP is located between the Npy's TATAbox and the TSS, whereas the human SNP is located upstream of the TATA-box) and, thus, extrapolation of the presented rat data into humans should be done with caution.
SNP-driven Npy expression and binding of CREB2. Sequence variants that alter gene expression by X1.5-fold have been found to predominantly localize in the core and proximal promoter gene regions. 49 Accordingly, using the FSL/FRL model we found that a SNP in the core promoter region of the rat Npy (C/T; rs105431668) was associated with a transcriptional programming. In particular, the FSL rats harbored the C-allele of rs105431668, which was associated with downregulated in vitro transcriptional activity. In addition, in vivo experiments revealed reduced Npy mRNA levels in the hippocampus of FSL, especially in the CA1 area; in accord with previous in situ experiments in the FSL model by Caberlotto et al. 23, 45 In line with a functional role of rs105431668, in vitro assays showed that the SNP's T-allele (present in homozygosity only in the FRL) accounts for a DNA-protein interaction. Subsequent in vivo experiments demonstrated an enrichment of the TF CREB2 (ATF4), only in the Npy promoter region of the FRL containing the T-allele of rs105431668. Cytosolic CREB2 is known to interact with metabotropic gamma-aminobutyric acid B receptors (GABA B R) and, upon receptor activation, CREB2 relocates to the nucleus where it exerts its transcriptional regulatory functions. 50 GABA B R and NPY coexist at GABAergic terminals of hippocampal interneurons, 51, 52 supporting a GABA B R-NPY regulatory pathway that is mediated by CREB2. As CREB2 is a known suppressor of long-term synaptic plasticity and memory, 53 extrapolating these data may indicate that NPY is also a downstream regulator involved in memory suppression. This hypothesis is consistent with NPY's inhibitory synaptic effects that involve inhibition of adenylyl cyclase (thus also of the production of cyclic adenosyl monophospate) through its binding to postsynaptic NPY-Y1 receptors. 51 Therefore, NPY's role in mental resilience may be to dampen the molecular effects of adverse experiences. These effects could involve long-term changes in synaptic strengths that get associated with negative memories. Such an assumption would be in line with findings in humans showing that the effect of rs16147 is modulated by early-life adversities 5, [19] [20] [21] and also with animal experiments showing that the FSL, but not the FRL, exhibit anhedonic responses only after chronic mild stress. 54 Allele-specific binding of Ep300 and corresponding HMs. Histone acetyltransferases Ep300 and CBP can be recruited to promoter regions by interacting with CREB proteins. [55] [56] [57] [58] PCAF, which binds to Ep300/CBP protein complexes, has also an intrinsic histone acetyltransferase activity. 59 In the present study, in vivo experiments supported an Ep300-binding to CREB2. More specifically, Ep300 was found to be enriched in its acetylated form, which has a higher catalytic activity, 60 solely in the FRL's Npy promoter region containing the T-allele of rs105431668. CREB2 interaction with Ep300 is known to induce CREB2 stabilization by inhibiting its ubiquitination. 61 As Ep300 is one of the main histone acetyltransferases necessary for in vivo maintenance of global H3K18ac, 62 we also performed in vivo experiments to analyze HMs at the Npy locus. Accordingly, we found that the FRL had elevated hippocampal levels of H3K18ac. Owing to lack of available antibody, we were not able to specifically screen for CBP; however, the absence of PCAF enrichment (that binds to the Ep300/CBP complex) provides indirect evidence against the presence of CBP at the Npy promoter region. H3K18ac is a HM that is associated with increased gene activity 63 and may account for the observed upregulated levels of Npy mRNA in the hippocampus of the FRL. Notably, CREB2 and Ep300 have also been shown to regulate cyclooxygenase-2 (COX-2). 64 COX-2 is expressed throughout the nervous system and is involved in inflammation. 65 Signs of inflammatory processes resulting from the function of COX-2 (for example, increased proinflammatory cytokines) have repeatedly been described in depression and COX-2 has been used as a target in pilot antidepressant studies. 66 Thus, the comorbidity of depression and inflammation may partly involve the action of CREB2, which relocates from the cytoplasm to the nucleus upon GABA B R activation 50 via, for example, a stressful event and in order to produce neuroprotective effects. This may also explain, for instance, why seizures have been found to stimulate both NPY and COX-2 expression in the hippocampus. 51, 67 Physical activity and epigenetic reprogramming of Npy. Experiments using the FSL/FRL model have previously shown that physical activity has antidepressant-like behavioral effects and increases both hippocampal neurogenesis and Npy expression. 32, 33, 36 In the present study, we found that FSL-runners had increased levels of hippocampal Npy mRNA and H3K18 acetylation. Notably, this increase was associated with a reduction in the mRNA levels of a specific histone modifying enzyme; Hdac5. HDAC5 is a class II HDAC known to interact with and repress myocyte enhancer factor-2 TFs needed for skeletal myogenesis. 68 More specifically, physical exercise and increases in motor neuron activity lead to a calcium influx that stimulates the expression of myocyte enhancer factor-2 responsive muscle-specific genes by phosphorylation-dependent inactivation and cytoplasmic translocation of nuclear class II HDACs. 68 The decreased levels of Hdac5 mRNA in FSL, as a response to physical activity, suggest a transcription-dependent regulation of Hdac5 in the hippocampus. This result is in line with a recent study investigating the expression of the brain-derived neurotrophic factor (Bdnf) gene in the rat hippocampus: physical activity was associated with an increase in H3 acetylation and Bdnf expression, and a decrease in HDAC5 protein and gene expression. 69 In addition, imipramine has been shown to increase histone acetylation of Bdnf and also selectively decrease Hdac5 mRNA levels in the mouse hippocampus. 70 As Bdnf and Npy are both considered resilience-conferring genes, 7 these data indicate commonalities in their regulatory pathways.
Conclusion
Our results suggest that the rat rs105431668 is a functional Npy SNP, which may explain depression-related molecular and behavioral characteristics of the FSL model. The presented data also provide clues about the epigenotypic architecture of depression by demonstrating how certain HMs are associated with Npy's transcriptional activity through allele-specific recruitment of certain TFs and coactivators. Additionally, even though genetic at its basis, the disadvantageous epigenetic state of Npy in the FSL was rescued by physical activity. Physical activity has been suggested to have antidepressant effects and recruit processes that confer stress resilience in humans. 71, 72 Physical activity intervention studies, in combination with molecular experiments exploring genes like NPY and BDNF, are thus warranted in clinical settings and could provide insights into novel non-pharmacological and pharmacological antidepressant treatments.
